

Preferred Practice Patterns

Resource	Address
Flaxel CJ, Adelman RA, Bailey ST, et al. Age-Related Macular Degeneration Preferred Practice Pattern® <i>Ophthalmology</i> . 2020;127(1):P1-P65. doi:10.1016/j.ophtha.2019.09.024	https://www.aaojournal.org/action/showPdf?pii=S0161-6420%2819%2932091-3
Flaxel CJ, Adelman RA, Bailey ST, et al. Diabetic Retinopathy Preferred Practice Pattern®. <i>Ophthalmology</i> . 2020;127(1):P66-P145. doi:10.1016/j.ophtha.2019.09.025	https://www.aaojournal.org/action/showPdf?pii=S0161-6420%2819%2932092-5

Unmet Needs in anti-VEGF Therapy

Resource	Address
Ciulla TA, Hussain RM, Pollack JS, Williams DF. Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: A real-world analysis of 49 485 Eyes. <i>Ophthalmol Retina</i> . 2020;4(1):19-30. doi:10.1016/j.oret.2019.05.017	https://pubmed.ncbi.nlm.nih.gov/31324588
Ciulla TA, Pollack JS, Williams DF. Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: A real-world analysis of 28 658 patient eyes. <i>Br J Ophthalmol</i> . 2021;105(2):216-221. doi:10.1136/bjophthalmol-2020-315933	https://pubmed.ncbi.nlm.nih.gov/32265201/
Ehlken C, Ziemssen F, Eter N, et al. Systematic review: Non-adherence and non-persistence in intravitreal treatment. <i>Graefes Arch Clin Exp Ophthalmol</i> . 2020;258(10):2077-2090. doi:10.1007/s00417-020-04798-2	https://pubmed.ncbi.nlm.nih.gov/32572607/
Gao X, Obeid A, Aderman CM, et al. Loss to follow-up after intravitreal anti-vascular endothelial growth factor injections in patients with diabetic macular edema. <i>Ophthalmol Retina</i> . 2019;3(3):230-236. doi:10.1016/j.oret.2018.11.002	https://pubmed.ncbi.nlm.nih.gov/31014699/
Greenlee TE, Wang VY, Kang H, et al. Consequences of lapses in treatment with vascular endothelial growth factor inhibitors in neovascular age-related macular degeneration in routine clinical practice. <i>Retina</i> . 2021;41(3):581-587. doi:10.1097/IAE.0000000000002888	https://pubmed.ncbi.nlm.nih.gov/32658164/

Obeid A, Gao X, Ali FS, et al. Loss to follow-up in patients with proliferative diabetic retinopathy after panretinal photocoagulation or intravitreal anti-VEGF injections. <i>Ophthalmology</i> . 2018;125(9):1386-1392. doi:10.1016/j.ophtha.2018.02.034	https://pubmed.ncbi.nlm.nih.gov/29606377/
---	---

Extending Time Between Treatment

Resource	Address
Chang MA, Kapre A, Kaufman D, et al. Patient preference and treatment satisfaction with a port delivery system for ranibizumab vs intravitreal injections in patients with neovascular age-related macular degeneration: A randomized clinical trial [published online ahead of print, 2022 Jun 16]. <i>JAMA Ophthalmol</i> . 2022;e221091. doi:10.1001/jamaophthalmol.2022.1091	https://pubmed.ncbi.nlm.nih.gov/35708706/
Dugel PU, Singh RP, Koh A, et al. HAWK and HARRIER: Ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. <i>Ophthalmology</i> . 2021;128(1):89-99. doi:10.1016/j.ophtha.2020.06.028	https://pubmed.ncbi.nlm.nih.gov/32574761/
Heier JS, Khanani AM, Ruiz CQ, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): Two randomised, double-masked, phase 3, non-inferiority trials. <i>Lancet</i> . 2022;399(10326):729-740. doi:10.1016/S0140-6736(22)00010-1	https://pubmed.ncbi.nlm.nih.gov/35085502/
Holekamp NM, Campochiaro PA, Chang MA, et al. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. <i>Ophthalmology</i> . 2022;129(3):295-307. doi:10.1016/j.ophtha.2021.09.016	https://pubmed.ncbi.nlm.nih.gov/34597713/
Iyer S, Radwan AE, Hafezi-Moghadam A, Malyala P, Amiji M. Long-acting intraocular delivery strategies for biological therapy of age-related macular degeneration. <i>J Control Release</i> . 2019;296:140-149. doi:10.1016/j.jconrel.2019.01.007	https://pubmed.ncbi.nlm.nih.gov/30660630/
Patel P, Sheth V. New and innovative treatments for neovascular age-related macular degeneration (nAMD). <i>J Clin Med</i> . 2021;10(11):2436. doi:10.3390/jcm10112436	https://pubmed.ncbi.nlm.nih.gov/34070899/

Sarohia GS, Nanji K, Khan M, et al. Treat-and-extend versus alternate dosing strategies with anti-vascular endothelial growth factor agents to treat center involving diabetic macular edema: A systematic review and meta-analysis of 2,346 eyes [published online ahead of print, 2022 Apr 25]. <i>Surv Ophthalmol</i> . 2022;S0039-6257(22)00047-9. doi:10.1016/j.survophthal.2022.04.003	https://pubmed.ncbi.nlm.nih.gov/35476929/
Wykoff CC, Abreu F, Adamis AP, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): Two randomised, double-masked, phase 3 trials. <i>Lancet</i> . 2022;399(10326):741-755. doi:10.1016/S0140-6736(22)00018-6	https://pubmed.ncbi.nlm.nih.gov/35085503/

Associations and Resources

Resource	Address
American Diabetes Association: Eye Complications	https://www.diabetes.org/diabetes/complications/eye-complications
American Macular Degeneration Foundation	https://www.macular.org/
American Society of Retina Specialists	https://asrs.org/
Solomon SD, Chew E, Duh EJ, et al. Diabetic retinopathy: A position statement by the American Diabetes Association. <i>Diabetes Care</i> . 2017;40(3):412-418. doi:10.2337/dc16-2641	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402875/pdf/dc162641.pdf
Macular Degeneration Association	https://macularhope.org